Tweets
Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
@RheumNow interview at #ACR24 with Dr Harry Hurley about A#1694
Should we do one or two lungs when transplanting for autoimmune related ILD?
https://t.co/2omSSAPvgi https://t.co/BlAQjuBRFt
Links:
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
How Online Searches Reveal Patient Needs
In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24
https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
A#2363
Deodhar
Bimekizumab fast time to work:
BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose.
@RheumNow #ACR24 https://t.co/T81Lzyoy7m
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it.
@rheumnow abst#2160 #ACR24
Bella Mehta @bella_mehta ( View Tweet )
1 year 5 months ago
In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study
Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr
Bella Mehta @bella_mehta ( View Tweet )
1 year 5 months ago
Reproductive Issues in axSpA: Fertility and Pregnancy
axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq
Links:
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
A#2291
ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens
Symptomatology is complex in SjD and beyond traditional disease activity markers
@RheumNow #ACR24 https://t.co/AhstAFjOVS
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex.
Race/ethnicity + income modify the effects
- Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities
@RheumNow #ACR24
Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 5 months ago
